Latest articles from Cancer Therapy Advisor Lung Cancer
Phase 1 trials of investigational drug candidates in oncology are increasing, likely as a way of involving more patients with rare tumors. from Latest articles from Cancer Therapy Advisor Lung Cancer https://ift.tt/2SuXXmS
The phase 3 CAUREL trial evaluating the combination of an anti-PD-L1 and an EGFR-TKI in advanced EGFR-mutant NSCLC was terminated early because of safety concerns from a related trial. from Latest articles from Cancer Therapy A…
Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services. from Latest articles from Cancer Therapy Advisor …
In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol. from Latest articles from Cancer Therapy Advisor Lung Cancer http://bit.ly/…
Currently used assays that gauge potential response to immune checkpoint inhibitors have limited predictive value, noted researchers. from Latest articles from Cancer Therapy Advisor Lung Cancer http://bit.ly/2GozaPG
"People have shown that the variant-identification quality of WGS is superior to WES," said Dr Gerstein. from Latest articles from Cancer Therapy Advisor Lung Cancer http://bit.ly/2GrL4se
"People have shown that the variant-identification quality of WGS is superior to WES," said Dr Gerstein. from Latest articles from Cancer Therapy Advisor Lung Cancer http://bit.ly/2Ib0XoE
Patient-reported outcomes, or PROs, are going to play a larger role in FDA cancer drug approvals, according to an expert in the field. from Latest articles from Cancer Therapy Advisor Lung Cancer http://bit.ly/2SITscq
Articles discussing the use of cannabis as a substitute for opioids highlight the limitations of the existing scientific evidence in the field. from Latest articles from Cancer Therapy Advisor Lung Cancer http://bit.ly/2SjbAKA�…
The continuous decline in cancer deaths over the past 25 years was attributed to improvements in screening, treatment. from Latest articles from Cancer Therapy Advisor Lung Cancer http://bit.ly/2HXijVI
Experts examined the role of population-based early detection cancer screening. from Latest articles from Cancer Therapy Advisor Lung Cancer http://bit.ly/2HPQ3ED
Researchers are excited about the prospect to use vaccines in combination with checkpoint inhibitors to improve the body's cancer-fighting ability. from Latest articles from Cancer Therapy Advisor Lung Cancer http://bit.ly/…
Assessments of MET copy number gain are not predictive of benefit from TKI therapy in EGFR-mutant NSCLC, according to researchers. from Latest articles from Cancer Therapy Advisor Lung Cancer http://bit.ly/2Ux8I9y
QoL for patients with cancer is reduced just as much by the accumulation of low-level toxicities as it is from high-level adverse events. from Latest articles from Cancer Therapy Advisor Lung Cancer http://bit.ly/2GcArIK
The Lung-MAP trial, which will allow multiple tumor biomarker-specific treatments to be evaluated in a single umbrella study, is now open to all patients with NSCLC. from Latest articles from Cancer Therapy Advisor Lung Cancer …
Researchers provide further proof that CRISPR can augment cancer treatment in the lab, but many barriers remain before clinical trials can be conducted in patients. from Latest articles from Cancer Therapy Advisor Lung Cancer h…
Individuals with early-stage EGFR-mutant NSCLC who were administered erlotinib showed improved 2-year DFS compared with genotype-matched historical controls. from Latest articles from Cancer Therapy Advisor Lung Cancer http://b…
The combination of trametinib and palbociclib induced attack by NK cells — but not killing — of xenograft lung tumors in lab animals. from Latest articles from Cancer Therapy Advisor Lung Cancer http://bit.ly/2Fz1tKi
Patients with malignant pleural effusion may care more about relieving symptoms such as dyspnea as opposed to achieving pleurodesis. from Latest articles from Cancer Therapy Advisor Lung Cancer http://bit.ly/2VMEVLq
Use of real-world data has the potential to accelerate drug and device approvals in rare diseases and advance precision medicine initiatives. from Latest articles from Cancer Therapy Advisor Lung Cancer http://bit.ly/2SNFQcG
